A Randomized, Double-Blind, 3-Arm, Parallel-Controlled Clinical Study to Compare the Pharmacokinetics, Safety, Tolerability and Immunogenicity of JHL1188 versus Herceptin (EU and US sourced) in Healthy Male subjects
Latest Information Update: 29 Mar 2022
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer; Gastric cancer
- Focus Pharmacokinetics
- Sponsors Eden Biologics
- 23 Nov 2020 New trial record
- 20 Nov 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.